Work

Randomized phase II trial of docetaxel (Doc) and prednisone (Pred) with or without AZD2171 (cediranib), in chemotherapy-naive, metastatic castrate-resistant prostate cancer (mCRPC) (NCI 7451).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.6_suppl.38

Authors: Elisabeth I. Heath, Heather Dorothy Mannuel, Glenn Liu, Primo Lara, J. P. Monk, Thomas W. Flaig, Amado J. Zurita, Ulka N. Vaishampayan, Philip J. Stella, Daryn W. Smith, Kimberlee Dobson, Arif Hussain, Anas Al-Janadi, S. Percy Ivy, Lance K. Heilbrun

Institutions: The Barbara Ann Karmanos Cancer Institute, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of California, Davis, The Ohio State University, University of Colorado Denver, The University of Texas MD Anderson Cancer Center, Wayne State University, Trinity Health Michigan, Trinity Health Ann Arbor Hospital, Michigan State University

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2589309657

Cites:

Cited by: 4

Related to: 10